Development and License Agreements - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2020	Sep. 30, 2024	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023
BARDA Agreement
Licenses Agreements [Line Items]
Additional committed fund receivable						$ 3,500,000
Committed fund receivable			$ 185,500,000	$ 185,500,000
Reduction in committed fund receivable				8,800,000
Committed fund receivable			270,200,000	270,200,000
Receivable of billed and unbilled amounts			1,800,000	1,800,000	$ 5,600,000
BARDA Agreement | Cerus Corporation | Maximum
Licenses Agreements [Line Items]
Co-investment by the company				1,400,000
2024 BARDA Agreement
Licenses Agreements [Line Items]
Committed fund receivable			32,100,000	32,100,000
Committed fund receivable			188,400,000	188,400,000
Revenues			0	0
2024 BARDA Agreement | Cerus Corporation | Maximum
Licenses Agreements [Line Items]
Co-investment by the company				60,100,000
FDA Agreement
Licenses Agreements [Line Items]
Contract agreement term		5 years
Total potential contract value		$ 11,100,000
FDA Agreement | Accounts Receivable, Net
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			700,000	700,000	500,000
DoD and IBAS Program Agreement | Accounts Receivable, Net
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			0	0	3,700,000
DoD and IBAS Program Agreement | Deferred Revenue
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			$ 700,000	$ 700,000	$ 1,500,000
DoD and IBAS Program Agreement | Maximum
Licenses Agreements [Line Items]
Total contract value	$ 17,800,000
DoD and IBAS Program Agreement | Minimum
Licenses Agreements [Line Items]
Total contract value	$ 9,100,000